Evolution of the Average Target: UCB

Evolution of the Target Price: UCB

Changes in Analyst Recommendations: UCB

1f5e90853d83b4c9fde48bb307706c9._gtvfRn5enpLissC_zmvXAkiV18GeeANbGGF0MMigd4.lGheNXPPDU9m-eZvr3buK1tLJypVPdZoORDm46RQ6eaKZjhFVL0AL3_QvA~ff78976ca8e576babad0363be1f20b3a
06-15 UCB Slumps Following Analyst Downgrade Zonebourse
06-15 Barclays Downgrades UCB to Equalweight, Trims PT MT
06-15 UCB Kept at Buy as BofA Notes Psoriasis Drug Momentum MT
06-09 UCB Favored by Oddo BHF Zonebourse
06-05 KBC Securities Maintains Buy Rating on UCB Zonebourse
05-21 UCB Price Target, Estimates Up as AlphaValue/Baader Europe Notes Growth Momentum MT
05-20 UCB: Executing well, but valuation lacks safety net Alphavalue
04-27 AlphaValue/Baader Europe Upgrades UCB to Reduce, Trims PT MT
03-30 MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says MT
03-16 Berenberg Keeps UCB Amid Positive Pipeline Progress, H2 Catalysts MT
02-26 UCB: H2 beat; 2026 outlook healthy; but valuation remains red-hot Alphavalue
02-24 Wolfe Research Kicks Off UCB Coverage at Outperform MT
02-02 UCB on Track for 'Impressive' Growth Acceleration, Says RBC MT
01-07 BofA Reaffirms UCB's Buy Rating on Upbeat FY26 Outlook MT
12-03 Berenberg Keeps UCB at Buy Amid Plan to Maximize Growth of Key Assets MT
25-10-29 UCB: UBS raises target price Zonebourse
25-10-14 Berenberg Says Higher Premium for UCB Pipeline Warranted; Price Target Raised MT
25-10-13 UCB Announces Results from Multicenter Retrospective Chart Review Study of Investigational Pyrimidine Nucleoside and/or nucleotide Therapy in Patients with Thymidine Kinase 2 Deficiency CI
25-10-07 AlphaValue/Baader Europe Lifts UCB Price Target Amid Strong Drug Demand MT
25-10-03 UCB: Untouchable UCB; despite our upgrade Alphavalue
25-09-29 MoonLake Shares Slide After Release of Skin Disorder Drug Trial Data, Multiple Downgrades MT
25-09-29 MoonLake Immunotherapeutics' Skin Disease Drug Hits Key Goals in Phase 3 Trials, Lags Behind UCB Rival MT
25-08-27 UCB: ING raises target price Zonebourse
25-08-25 Bank Degroof Petercam Upgrades UCB to Buy, Boosts PT MT
25-07-31 UCB: Vigorous H1, though shares remain expensive Alphavalue

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+35.56%
+57.25%
+28.81%
+12.53%
-21.84%
+9.36%
+53.83%
+9.59%
+53.48%
Average +26.51%
Weighted average by Cap. +29.02%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
252.40EUR
Average target price
292.44EUR
Spread / Average Target
+15.87%
High Price Target
340.00EUR
Spread / Highest target
+34.71%
Low Price Target
195.00EUR
Spread / Lowest Target
-22.74%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Barclays
alphavalue Abhishek Raval
AlphaValue/Baader Europe
Wolfe Research
Bank Degroof Petercam
Morgan Stanley
Intron Health
Sadif Investment Analytics
Kempen
KBC Securities
ODDO BHF
Kepler Cheuvreux
Berenberg Bank
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
252.40EUR
Average target price
292.44EUR
Spread / Average Target
+15.87%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!